American College of Cardiology Names Ravee Kurian COO/CFO

American College of Cardiology reports Ravee Kurian has been named Executive Vice President and Chief Operating Officer/Chief Financial effective July 1. Kurian will lead the global organization’s strategic planning, finance and technology divisions, while working closely with the ACC’s leadership team to advance the College’s digital transformation initiatives.

When the world was hit by the biggest public health crisis of our lifetimes, the ACC’s Board and Staff pivoted quickly to accommodate the rapidly shifting needs of the organization and its members,” Kurian said. “The ACC’s ability to do this without skipping a beat demonstrated exceptional levels of professionalism and commitment by every single person involved. I am honored and humbled to join this dedicated group as a member of the leadership team and I look forward to helping the College move confidently into the future.”

Kurian comes to ACC following a 20-year stint at Publicis Sapient, a leading technology and communications consultancy, where he led critical and sensitive digital transformation initiatives for Fortune 500 and U.S. federal clients.

Over the course of his career, Kurian has worked in a broad range of industries, including aerospace, trucking, insurance, defense and medical research. His most recent experience has been at the National Institutes of Health (NIH) where he worked with researchers, physicians and content strategists to develop a digital-first mindset that helped align their technology investments with how their audiences were interacting with their content. Previously, he also worked at Ernst & Young and at Landauer Associates, a real estate valuation and research firm.

Kurian holds a Master of Business Administration from the Kellogg School of Management at Northwestern University and a Bachelor of Science from the University of Massachusetts at Amherst.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”